A Randomized, 2-Part, Single-Dose, Crossover Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval in Healthy Participants
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Aficamten (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- Sponsors Cytokinetics
Most Recent Events
- 15 Dec 2023 Status changed from active, no longer recruiting to completed.
- 18 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2023 New trial record